New England Research & Management Inc. Grows Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

New England Research & Management Inc. boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 94.3% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 2,215 shares of the medical research company’s stock after purchasing an additional 1,075 shares during the period. New England Research & Management Inc.’s holdings in Thermo Fisher Scientific were worth $1,370,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth about $382,000. Personal CFO Solutions LLC lifted its holdings in Thermo Fisher Scientific by 2.1% during the 4th quarter. Personal CFO Solutions LLC now owns 2,110 shares of the medical research company’s stock worth $1,120,000 after buying an additional 43 shares in the last quarter. Ossiam boosted its position in Thermo Fisher Scientific by 5.1% in the 4th quarter. Ossiam now owns 9,217 shares of the medical research company’s stock valued at $4,892,000 after buying an additional 447 shares during the period. Elo Mutual Pension Insurance Co boosted its holdings in Thermo Fisher Scientific by 4.4% in the fourth quarter. Elo Mutual Pension Insurance Co now owns 33,696 shares of the medical research company’s stock valued at $17,885,000 after purchasing an additional 1,413 shares during the period. Finally, State of Tennessee Treasury Department increased its holdings in Thermo Fisher Scientific by 29.0% during the 4th quarter. State of Tennessee Treasury Department now owns 159,098 shares of the medical research company’s stock worth $84,448,000 after purchasing an additional 35,732 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $0.24 during trading on Monday, reaching $598.85. The company’s stock had a trading volume of 1,114,318 shares, compared to its average volume of 1,474,026. The business has a 50 day moving average price of $609.46 and a 200-day moving average price of $582.80. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $627.88. The company has a market capitalization of $228.76 billion, a P/E ratio of 38.39, a price-to-earnings-growth ratio of 3.88 and a beta of 0.77. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The business had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $5.15 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Analyst Ratings Changes

TMO has been the topic of several analyst reports. TD Cowen raised their target price on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Robert W. Baird boosted their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Stephens initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target on the stock. Evercore ISI increased their price objective on Thermo Fisher Scientific from $605.00 to $630.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Royal Bank of Canada restated an “outperform” rating and set a $767.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $653.72.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock worth $14,094,292 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.